NYSE:EBS Emergent Biosolutions (EBS) Stock Price, News & Analysis $8.19 +2.16 (+35.84%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$8.13 -0.06 (-0.74%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Emergent Biosolutions Stock (NYSE:EBS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emergent Biosolutions alerts:Sign Up Key Stats Today's Range$6.49▼$8.2550-Day Range$5.63▼$8.1952-Week Range$4.02▼$13.28Volume5.78 million shsAverage Volume1.04 million shsMarket Capitalization$444.61 millionP/E Ratio3.34Dividend YieldN/APrice Target$14.33Consensus RatingBuy Company Overview Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Read More Emergent Biosolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreEBS MarketRank™: Emergent Biosolutions scored higher than 97% of companies evaluated by MarketBeat, and ranked 80th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEmergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEmergent Biosolutions has received no research coverage in the past 90 days.Read more about Emergent Biosolutions' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent Biosolutions is 3.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent Biosolutions is 3.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.87.Price to Book Value per Share RatioEmergent Biosolutions has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.45% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Emergent Biosolutions has recently decreased by 9.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent Biosolutions does not currently pay a dividend.Dividend GrowthEmergent Biosolutions does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.40 Percentage of Shares Shorted17.45% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Emergent Biosolutions has recently decreased by 9.49%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.79 News SentimentEmergent Biosolutions has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Emergent Biosolutions this week, compared to 5 articles on an average week.Search Interest5 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Emergent Biosolutions to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,417.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent Biosolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent Biosolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Stock News HeadlinesEmergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call TranscriptAugust 7 at 8:04 PM | seekingalpha.comEmergent BioSolutions Surpasses Q2 Revenue ExpectationsAugust 6 at 4:40 PM | tipranks.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities. | Brownstone Research (Ad)Emergent BioSolutions Reports Second Quarter 2025 Financial ResultsAugust 6 at 4:15 PM | globenewswire.comA Preview Of Emergent BioSolutions's EarningsAugust 6 at 2:51 AM | benzinga.comHead to Head Comparison: Emergent Biosolutions (NYSE:EBS) & Celularity (NASDAQ:CELU)August 1, 2025 | americanbankingnews.comNew Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for MpoxJuly 28, 2025 | globenewswire.comEmergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of RepresentativesJuly 28, 2025 | globenewswire.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent Biosolutions' stock was trading at $9.56 on January 1st, 2025. Since then, EBS stock has decreased by 14.3% and is now trading at $8.1910. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc. (NYSE:EBS) announced its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.42. The biopharmaceutical company earned $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. Emergent Biosolutions had a trailing twelve-month return on equity of 24.89% and a net margin of 16.38%. Read the conference call transcript. Is Emergent Biosolutions doing a stock buyback? Emergent Biosolutions' Board of Directors initiated a stock buyback program on Monday, March 31st 2025, which allows the company to buy back $50,000,000 in shares, according to EventVestor. This means that the company could buy up to 19% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its stock is undervalued. Who are Emergent Biosolutions' major shareholders? Top institutional shareholders of Emergent Biosolutions include Connor Clark & Lunn Investment Management Ltd. (1.82%), Acadian Asset Management LLC (1.80%), Prescott Group Capital Management L.L.C. (1.42%) and Assenagon Asset Management S.A. (0.57%). Insiders that own company stock include Neal Franklin Fowler, Keith Katkin, Kathryn C Zoon and Ronald Richard. View institutional ownership trends. How do I buy shares of Emergent Biosolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,420Year FoundedN/APrice Target and Rating Average Price Target for Emergent Biosolutions$14.33 High Price Target$16.00 Low Price Target$12.00 Potential Upside/Downside+75.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.71) Trailing P/E Ratio3.34 Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.60 million Net Margins16.38% Pretax Margin-6.45% Return on Equity24.89% Return on Assets8.95% Debt Debt-to-Equity Ratio1.20 Current Ratio6.32 Quick Ratio3.51 Sales & Book Value Annual Sales$1.04 billion Price / Sales0.43 Cash Flow$2.61 per share Price / Cash Flow3.14 Book Value$8.91 per share Price / Book0.92Miscellaneous Outstanding Shares54,280,000Free Float53,627,000Market Cap$444.61 million OptionableOptionable Beta1.97 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:EBS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.